golotimod
Peptideexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2008 (NCT00756951)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Toll-like receptor 2Immunity, active
TLR2 immunity, active
Chemistry & pharmacology
Loading structure…
SMILES
N[C@H](CCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O)C(=O)O- Mol. weight
- 333.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2103812 ↗
Also known as
- gamma-d-glutamyl-l-tryptophan
- golotimod
- golotimod
- golotimod
- golotimod
- scv-07
- scv-07
- scv-07
- scv-07
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01247246 | Phase 2 | Dec 1, 2010 | SciClone Pharmaceuticals |
| NCT00968357 | Phase 2 | Sep 1, 2009 | SciClone Pharmaceuticals |
| NCT00756951 | Phase 2 | Sep 1, 2008 | SciClone Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SciClone Pharmaceuticals | For profit | 3 | 3 | 1 | 2008 |
1 organizations
Page 1 / 1